Skip to main content
Hansa Biopharma logo

Hansa Biopharma — Investor Relations & Filings

Ticker · HNSA ISIN · SE0002148817 LEI · 549300LLEO25ZJJ3NT91 ST Manufacturing
Open in API
Filings indexed 501 across all filing types
Latest filing 2015-12-08 Share Issue/Capital Cha…
Country SE Sweden
Listing ST HNSA

About Hansa Biopharma

https://www.hansabiopharma.com/

Hansa Biopharma is a commercial-stage biopharmaceutical company that develops and commercializes treatments for rare immunologic diseases. The company's core focus is its proprietary antibody-cleaving enzyme technology platform, designed to target and inactivate immunoglobulin G (IgG) antibodies. This approach aims to inhibit harmful IgG-mediated immune responses. Its lead product, imilfidase, is used to enable kidney transplantation in highly sensitized patients who have a low probability of finding a compatible donor. The company is also advancing its enzyme technology to address unmet medical needs in other therapeutic areas, including acute autoimmune diseases, gene therapy, and oncology, where IgG antibodies can be a barrier to treatment or a driver of the disease.

Recent filings

Filing Released Lang Actions
Svenska och internationella investerare förvärvar 2 miljoner aktier i Hansa Medical från Farstorps Gård AB
Share Issue/Capital Change Classification · 95% confidence The document is a press release dated December 8, 2015, announcing that Farstorps Gård AB sold 2 million shares of Hansa Medical AB to investors via an accelerated bookbuilding process. It also mentions the CEO acquired 30,000 shares. This transaction involves a significant change in share ownership and executive dealing, but the core event is the sale/acquisition of shares by insiders/major shareholders. Since the document explicitly details the transaction of shares by the CEO and a major shareholder sale, it relates to insider trading or significant shareholding changes. However, the primary focus is the transaction itself, which falls under Capital/Financing Update (CAP) if it were a primary issuance, or Major Shareholding Notification (MRQ) if it were just reporting the resulting holding. Given the context of a large block trade involving the CEO's personal acquisition, it strongly suggests insider activity or a significant capital structure movement. Since it is a report of a transaction involving existing shares and executive participation, it aligns best with either DIRS (Director's Dealing, as the CEO bought shares) or MRQ (Major Shareholding Notification, due to the large block trade). Because the CEO's personal acquisition is highlighted alongside the major sale, and the document is a formal announcement of a transaction, 'Transaction in Own Shares' (POS) is usually for buybacks/treasury stock, which this is not. 'Director's Dealing' (DIRS) covers personal share transactions by directors. Since the CEO bought shares, DIRS is a strong candidate. However, the overall event is a large block trade that changes ownership structure significantly. Given the options, and focusing on the transaction of shares by management, DIRS is appropriate. If the focus was purely on the resulting ownership percentage crossing a threshold, MRQ would fit. Since the text details the CEO's personal acquisition, DIRS is the most specific fit for the management action described within the larger transaction context. Alternatively, since it's a major change in ownership structure announced via press release, it could be classified as a general Regulatory Filing (RNS) if DIRS is too narrow, but DIRS is available. I will select DIRS based on the CEO's direct participation in acquiring shares.
2015-12-08 Swedish
Swedish and international investors acquire 2 million shares in Hansa Medical AB from Farstorps Gård AB
Director's Dealing Classification · 95% confidence The document is a press release dated December 8, 2015, announcing that a major shareholder (Farstorps Gård AB) sold 2 million shares in Hansa Medical AB via an accelerated bookbuilding process to other investors. It also notes that the CEO acquired 30,000 shares in the same transaction. This activity directly relates to changes in share ownership and insider transactions. While it involves a transaction, the core event is the sale/acquisition of shares by insiders and major shareholders. This fits best under 'Major Shareholding Notification' (MRQ) or potentially 'Director's Dealing' (DIRS) due to the CEO's purchase, but since the primary focus is the large block sale by a major shareholder, MRQ is a strong candidate. However, the CEO's personal acquisition is explicitly mentioned, which aligns perfectly with DIRS (Report of personal share transactions by company directors and executives). Given the dual nature, let's re-evaluate the definitions. DIRS focuses on *directors and executives*. MRQ focuses on *significant share ownership levels* crossing thresholds. Since the CEO's dealing is explicitly detailed alongside the major block trade, and the CEO is an executive, DIRS is highly relevant. If the document were purely about the major shareholder selling, MRQ would be better. Since the CEO's personal transaction is highlighted, DIRS is the most specific fit for the insider element, although MRQ is also plausible for the block trade aspect. Given the context of insider trading reports often capturing executive transactions, I will classify this as DIRS, as the CEO's transaction is a key component.
2015-12-08 English
Well attended Capital Markets Day by Hansa Medical
Investor Presentation Classification · 95% confidence The document text explicitly describes an event titled 'Capital Markets Day' held on November 13, 2015. It details the presentations given by the CEO, CSO, and various external experts regarding the company's clinical program (IdeS) and strategy. This content aligns perfectly with the definition of materials shared during an Annual General Meeting (AGM) or a similar investor briefing event, which is best categorized as AGM-R (AGM Information) or potentially Investor Presentation (IP). Since it is a summary of a formal, scheduled investor event featuring high-level updates and expert commentary, AGM-R is the most appropriate fit, as Capital Markets Days often serve a similar function to AGMs in terms of comprehensive updates, though IP is also plausible. Given the structure and purpose described, AGM-R is selected.
2015-11-13 English
Välbesökt på Hansa Medicals kapitalmarknadsdag
Investor Presentation Classification · 95% confidence The document is explicitly titled as a 'PRESSMEDDELANDE' (Press Release) dated November 13, 2015, announcing the company's 'kapitalmarknadsdag' (Capital Markets Day). It summarizes presentations given by management and external experts regarding the company's leading product (IdeS), clinical trials (Phase II), and future outlook. A Capital Markets Day presentation, which involves detailed strategic and scientific updates for investors, aligns best with the Investor Presentation (IP) category. Although it is a press release announcing the event, the content provided is the substance of the presentation itself, not just a brief announcement that a report is attached (which would suggest RPA or RNS). Since 'IP' covers detailed presentations for investors focusing on financials, strategy, and market position, this is the most appropriate classification.
2015-11-13 Swedish
Data som visar att IdeS kan inaktivera minnes-B-celler publicerade i Journal of Immunology
Regulatory Filings Classification · 95% confidence The document is explicitly labeled as a "PRESSMEDDELANDE" (Press Release) dated November 10, 2015. It announces that scientific data regarding the company's product (IdeS) has been published in the *Journal of Immunology*. The text focuses on communicating new scientific findings and their potential therapeutic implications, rather than presenting comprehensive financial results (like 10-K or IR) or being a transcript (CT). Since it is an announcement about scientific progress and potential therapeutic applications, it is best classified as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were a slide deck, but given the format and content (a news announcement about a publication), RNS is the most appropriate general regulatory/news category for non-standard financial disclosures. However, reviewing the definitions, this is a scientific/research update announcement. It is not a standard financial report (10-K, IR, ER, MRQ). It is not a management change (MANG), director dealing (DIRS), or dividend notice (DIV). It is an announcement of research results being published. This type of announcement, which is not a core financial filing but is material news, often falls under general regulatory announcements. Given the options, RNS (Regulatory Filings / miscellaneous announcements) is the best fit for a press release announcing a scientific publication, as it doesn't fit the more specific categories like ER, IR, or CAP.
2015-11-10 Swedish
Data showing that IdeS can silence memory B-cells published in Journal of Immunology
Regulatory Filings Classification · 95% confidence The document is explicitly labeled as a "PRESS RELEASE" dated November 10, 2015. It announces that scientific results regarding their product IdeS have been published in the *Journal of Immunology*. The text focuses on scientific findings, therapeutic potential, and provides background on the company and the product. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). Since it is a general announcement about scientific progress and publication, and it doesn't fit the specific categories like DIRS, DIV, or CAP, it falls best under the general regulatory announcement category, RNS, as it is a public disclosure mandated by securities laws (as noted in the final sentence: "The information was released for public disclosure on November 10, 2015"). It is not an announcement *of* a report being available (RPA), but rather the content of the announcement itself.
2015-11-10 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.